N/A
N=60
Effects of Electrical Muscle Stimulation on Waist Circumference in Adults
Abdominal Obesity
Bottom Line
View on ClinicalTrials.gov: NCT02970812 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcome: Primary: Waist Circumference — 87.0; 89.4 cm
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Electrical Muscle Stimulation (Device); Transcutaneous Electrical Nerve Stimulation (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pusan National University Yangsan Hospital
- Primary completion
- May 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Waist Circumference |
87.0; 89.4 | — |
Summary
This randomized, placebo-controlled, double-blind, controlled study was designed to investigate the efficacy of electrical muscle simulation (EMS) for treatment of waist circumference (WC) reduction in abdominal obese adults.
60 patients with abdominal obese, man with WC > 90 cm and woman with WC > 80 cm, received EMS as experimental group (EG) or transcutaneous electrical nerve stimulation (TENS) as control group (CG) 5 times a week for 12 weeks.
Eligibility Criteria
Inclusion Criteria
- Subject has abdominal obese seventy subjects between the age 18 and 65 years
- Abdominal obesity was defined as having a waist circumference (WC) >90 cm for men or WC >80 cm for women was defined based on the Asia-Pacific criteria of the International Diabetes Federation.
Exclusion Criteria
- pregnant or breastfeeding, had taken any treatment for weight loss or any medication known to affect weight
- had a weight loss of 3% or more in the preceding 3 months, had undergone any major surgery during the 1 year prior to study commencement
- had any inserted metallic materials including a pacemaker.
- aspartate aminotransferase or alanine aminotransferase of 100 mg/dL or more
- serum creatinine of 1.5 mg/dL or more
- a history of coronary arterial disease or cerebrovascular disease, impairment of a major organ system, cancer, severe lung diseases, severe cerebral trauma, uncontrolled hypertension and psychiatric diseases including eating disorder, etc.
Data sourced from ClinicalTrials.gov (NCT02970812). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.